RecruitingNCT05939401

A Study Regarding Tissue Response During and After Treatment for Anal Cancer

ANCABio - a Study Regarding Tumour Microenvironment and the Predictive Capability of Biopsies from Anal Cancer in Predicting Response and Outcome

Sponsor

Sahlgrenska University Hospital

Enrollment

400 participants

Start Date

Dec 1, 2023

Study Type

OBSERVATIONAL

Conditions

Anal Cancer

Summary

The aim of this study is to improve the understanding for the tumour biology in relation to treatment response in patients with anal cancer by examining: * The tumour microenvironment * The localisation of and cellular interactions between the tumour and immune cells * The gene and protein expression by cells present in the tumour and surrounding tissue.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue and blood samples from patients with anal cancer at different points during and after treatment to understand how the tumor and immune system change in response to therapy. **You may be eligible if...** - You have been newly diagnosed with anal cancer, or have a recurrence of anal cancer - You are able to provide blood samples and undergo biopsies **You may NOT be eligible if...** - You do not have a confirmed diagnosis of anal cancer - You have conditions that make biopsies unsafe (such as bleeding disorders or other contraindications) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.